+1.925.223.6233

In fact, Overall, Choosing a dependable online casino demands calm judgement, because the conditions shape the experience much more bold slogans. Keep in mind that To get a practical starting point, many readers frequently look at blik online casino, assuming they study the details carefully. Also, Welcome offers look tempting, yet their real value rests on the wagering terms, which deserve a close look. Banking methods need to be convenient, and the withdrawal speed is usually one of the most telling signs of a fair brand. Also, The range of titles tends to be broad, from video slots to roulette, giving players real choice. Also, Live dealer play appeals to players with real-time streams, and the stream quality shape the whole atmosphere. Also, A responsive help desk makes the difference whenever questions arise, especially if live chat are on hand. Also, Payouts reveal the true character behind a casino, so clear limits and quick processing build confidence. Also, Sensible gaming should stay central, so reality checks and clear budgets truly protect the user. Moreover, Besides, A proper licence is the essential thing to verify, because it shows that the platform respects clear requirements. Moreover, Besides, Promotions draw attention, yet their true worth depends on the playthrough conditions, which reward a calm review. Besides, Deposit choices ought to be flexible, and the payout time is often one of the clearest marks of a serious site. Moreover, Besides, The selection is generally wide, from classic slots to baccarat, offering fans plenty of options. Moreover, Besides, A live lobby attracts users with real dealers, and the betting limits define the entire session. Moreover, Besides, Good customer service sets the standard when problems show up, particularly if clear answers are easy to reach. Moreover, Besides, Cash-outs show the real nature of a casino, so reasonable checks and prompt handling inspire loyalty. Moreover, Besides, Safer gambling has to stay a priority, so deposit limits and calm habits really support the account holder. Moreover, Furthermore, A proper licence is the key thing to confirm, because it shows that the platform follows clear rules. Moreover, Furthermore, Promotions catch the eye, yet their actual benefit depends on the playthrough conditions, which deserve a calm read. When all is said and done, All in all, a thoughtful choice rests on clear terms, so compare calmly, check the rules and keep control. Uma boa referência costuma ser cassinos estrangeiros online, desde que você verifique os detalhes do site, ao invés de apenas ao visual do site. A seção ao vivo cativa o público devido aos crupiês profissionais, sendo que a qualidade do stream determina a imersão do jogador de forma significativa a cada rodada. O atendimento faz diferença, sobretudo quando aparecem problemas, portanto uma resposta rápida deve estar disponível 24 horas por dia, proporcionando uma experiência tranquila em qualquer situação. A agilidade dos pagamentos reflete a qualidade do serviço, portanto termos claros de retirada indicam qualidade a longo prazo para o jogador. O entretenimento controlado precisa ser o foco principal, portanto limites de depósito efetivamente promovem hábitos saudáveis de maneira eficaz no longo prazo. O registro regulatório é o sinal mais claro de confiança, pois assegura regras claras, o que merece atenção antes do cadastro, idealmente com atenção. As promoções chamam atenção, mas seu valor real esconde-se nos detalhes, por isso vale a pena ler cada exigência sem pressa. As formas de depósito devem ser variados e confiáveis, e a velocidade das transações geralmente indica o nível da plataforma, aspecto que deve ser avaliado antes de se cadastrar. A biblioteca de títulos costuma ser rico em opções, desde jogos de máquina até pôquer e bacará, o que contempla todo tipo de usuário. O cassino ao vivo atrai jogadores devido aos dealers reais, pois a qualidade do stream determina a experiência de jogo consideravelmente em cada partida. A assistência ao usuário tem grande valor, especialmente quando aparecem problemas, por isso um atendimento eficiente deve estar disponível 24 horas por dia, garantindo uma jogada confortável a todo momento. A velocidade dos saques reflete a seriedade da plataforma, então termos claros de retirada geram confiança de forma consistente para o usuário. O jogo responsável precisa ser uma prioridade, então limites de depósito efetivamente protegem o jogador com resultados positivos na rotina de apostas. O registro regulatório representa o sinal mais claro de confiança, pois confirma a fiscalização, o que traz tranquilidade logo no início, preferencialmente sem pressa. As promoções são atrativos, mas seu valor real depende das condições de apostas, por isso é preciso verificar as condições detalhadamente antes de aceitar. Por fim a decisão certa vem de análise, então pesquise com atenção, verifique os termos e condições e estabeleça seus limites. K tomu, Praktickym prikladem je vetsinou mobilní casino Česko, za predpokladu ze posoudite to v klidu, misto duvery v reklamu, celkem rozumne. Dale, Aktualni licence je temer vzdy klicovy prvek bezpeci, ponevadz zarucuje jasna pravidla, co netreba prehlizet hned na zacatku. Dale, Akce delaji dojem, nicmene jejich opravdovy zisk plyne z podminek, proto je je treba precist bez spechu. Dale, Zpusoby vkladu by mely byt flexibilni, a soucasne doba zpracovani zpravidla svedci o poctivosti, cemu venujte pozornost. Navic, Nabidka her obvykle je pestra, od her s jackpotem po bakarat, a tim zajistuje pestrost na dlouho. Dale, Rezim live dela dojem diky autenticke atmosfere, a pritom rozsah sazek rozhoduje o zazitku kazde partie. Dale, Dobra zakaznicka podpora buduje duveru, zejmena kdyz neco je treba vysvetlit, a tak by jasna vysvetleni maji cenu zlata v pripade potreby. Dale, Vyplaceni vyher prozrazuji pravdu o kvality sluzby, a tak rychle zpracovani davaji klid casem. Dale, Bezpecne hrani vzdy ma vyznam, a tak moznost sebevylouceni citelne pomahaji zachovat rozum bezne. Krome toho, Aktualni licence je vzdy prvni vec ke kontrole, jelikoz dokazuje legalitu, co netreba prehlizet jeste pred vkladem. Krome toho, Akce pritahuji pozornost, avsak jejich realny prinos se skryva v pravidlech, proto je je treba precist pozorne. Krome toho, Zpusoby vkladu by mely byt bezpecne, a rychlost vyplat obvykle svedci o poctivosti, co lze snadno prehlednout. Herni knihovna obvykle je bohata, od klasickych automatu po blackjack, cimz zajistuje pestrost bez nudy. Krome toho, Rezim live budi emoce diky skutecnym krupierum, a zaroven pocet stolu rozhoduje o zazitku vecera u hry. Krome toho, Dobra zakaznicka podpora ma velky vyznam, zejmena kdyz vyvstanou otazky, a proto by rychle odpovedi maji cenu zlata kdykoli. Krome toho, Vyplaceni vyher nejvic vypovidaji o poctivosti kasina, a proto rozumne podminky davaji klid kazdy den. Krome toho, Bezpecne hrani musi zustat dulezita, proto pripominky casu opravdu pomahaji zachovat rozum z dlouhodobeho hlediska. Platna licence je zpravidla klicovy prvek bezpeci, protoze potvrzuje dohled regulatora, co netreba prehlizet nez zacnete hrat. Bonusy vypadaji atraktivne, nicmene jejich skutecna hodnota zavisi na podminkach sazeni, proto je je treba precist s rozvahou. Platebni metody by mely byt rychle, a soucasne doba vyplaty casto svedci o poctivosti, co dela rozdil. Nabidka her byva impozantni, od her s jackpotem po ruletu, coz zajistuje pestrost kdykoli. Celkove, V dusledku uvazene rozhodnuti vychazi z analyzy, takze porovnavejte s chladnou hlavou, ctete pozorne pravidla a stanovte si limity. 安な カジノ を 利用する 際 には 丁寧 に 確認 する こと が 重要 です、なぜなら 条件 の 詳細 が 選択 を 大きく 決める から; 常に 詳細 を 丁寧 に 分析 し てから 金 する の が 賢明 です。 また、信頼できる 候補 として は よく 知られている オンラインカジノ 本人確認不要、条件 として 落ち着いて 条件 を 比較 すれ ば、最適 な 判断 が でき ます。 また、なお、その他にも、各種 キャンペーン は 目を 引き ます、ただし 実際 の 価値 は 条件 の 中 に あります。そのため 重 に 詳細 を 確かめ てから 受け取る こと を お勧め します。 また、決済 オプション は 多様 で 安 で ある べき です。取引 の 完了 スピード は 多く の 場合 運営 の 姿勢 を 表します。これ は プレイ 開始 前 に 確認 する 価値 が ある 重要 な 点 です。 その上、さらに、コンテンツ の 実度 は 一般 的 に 非常 に 豊富 で 多様 です。人気 の スロット から ルーレット や ブラックジャック まで、異なる 好み の 利用 に 対応 して います。 加えて、なお、ライブ カジノ は ライブ 信 の おかげ で 多く の プレイヤー を 了 します。映像 の スムーズさ が 没感 を 大きく 左右 します。 また、ユーザー サポート は 特 に 助け が 要 な とき に 大きな 差 を 生み ます。効率 的 な サポート が 要 な とき に 利用 できる こと が 重要 です。 加えて、なお、出金 の 速さ は 運営 の 姿勢 を 最も よく 示します。わかりやすい 取引 条件 が 長期 的 な 信頼 を 築き ます。 なお、さらに、コントロール された 娯楽 は 優 事 で ある べき です。支出 管理 機能 の 利用 が バランス の とれた 生活 を 促し 長期 的 に 役立ち ます。 加えて、また、なお、正規 の ライセンス は 通常 最も 明確 な 信頼 の 証 で あり、それ は 規制 当局 の 監督 を 確認 する から。これ は 初回 金 前 に 丁寧 に 確認 すべき 大切 な 事 です。 また、さらに、特 の 数 は 目を 引き ます、しかし 本当 の メリット は 条件 の 中 に あります。そのため じっくり と 条件 を 確認 し てから 判断 する の が 賢明 です。 その上、その他にも、 出金 方法 は 便利 で 信頼できる べき です。取引 の 完了 スピード は 多く の 場合 カジノ の レベル を 示します。これ は 登録 前 に チェック しておく べき ポイント です。 加えて、また、なお、コンテンツ の 実度 は 通常 実 しており 選択肢 が 豊富 です。人気 の スロット から ルーレット や ブラックジャック まで、多様 な ニーズ の ユーザー に 合わせて います。 最終的 に は 最適 な 判断 は 事実 に 基づく もの です。そのため 重 に 評価 し、条件 を 検証 し、コントロール を 保ち ながら 楽しむ こと が 大切 です。 Overall, Choosing a trustworthy online casino takes careful thought, because the details truly matter much more bold slogans. Importantly, Keep in mind that To get a solid starting point, many readers often look at best bitcoin casino australia, assuming they read the terms carefully. Furthermore, The game library is usually wide, from classic slots to blackjack, offering fans genuine variety. Furthermore, A live casino draws in users with real dealers, and the table range define the entire experience. Furthermore, Helpful support marks the standard when issues appear, particularly if clear answers are available. Furthermore, Withdrawals expose the real nature of a casino, so fair terms and prompt handling inspire trust. Furthermore, Responsible play must remain a priority, so deposit limits and firm rules really support the player. A valid licence is the first thing to confirm, because it shows that the casino follows firm standards. Bonuses look tempting, yet their actual benefit depends on the rollover rules, which deserve a careful look. Payment options should be convenient, and the cash-out period is often one of the most useful signs of a honest brand. The game library tends to be generous, from classic slots to blackjack, giving users real choice. A live casino appeals to fans with real dealers, and the table range shape the overall atmosphere. Helpful support makes the tone when issues appear, especially if quick replies are on hand. Withdrawals reveal the honest side of a casino, so fair terms and quick processing earn confidence. Responsible play should stay in focus, so deposit limits and firm rules truly safeguard the user. Moreover, In addition, A valid licence is the first thing to check, because it shows that the operator meets strict requirements. Moreover, In addition, Bonuses look tempting, yet their real value depends on the wagering terms, which repay a close review. Besides, Banking methods should be convenient, and the withdrawal speed is often one of the most telling indicators of a fair site. Moreover, In addition, The game library tends to be broad, from classic slots to roulette, bringing players plenty of options. Moreover, In addition, A live casino appeals to players with real dealers, and the stream quality drive the whole session. To summarize, When all is said and done, All in all, a sensible choice rests on facts, so compare calmly, read closely and keep control. Em geral, Uma opção interessante pode ser casa de aposta sem verificação de identidade, desde que você verifique as condições disponíveis, ao invés de apenas ao visual da plataforma. O catálogo de jogos é normalmente diversificado e atrativo, incluindo desde caça-níqueis tradicionais até pôquer e bacará, o que agrada variados gostos. A seção ao vivo cativa o público por conta dos crupiês profissionais, sendo que a qualidade do stream determina a experiência de jogo de forma significativa durante toda a sessão. A assistência ao usuário faz diferença, sobretudo quando é preciso ajuda, portanto uma resposta rápida deve estar disponível 24 horas por dia, garantindo uma experiência tranquila quando precisar. A agilidade dos pagamentos demonstra a qualidade do serviço, portanto termos claros de retirada geram confiança a longo prazo para quem aposta. O entretenimento controlado tem que ser o foco principal, portanto limites de depósito efetivamente protegem o jogador de maneira eficaz ao longo do tempo. O registro regulatório é a garantia básica de proteção, pois assegura regras claras, o que traz tranquilidade logo no início, de preferência com calma. As promoções chamam atenção, contudo seu valor real esconde-se nos detalhes, por isso é preciso verificar os termos com cuidado com calma. As formas de depósito devem ser ágeis e protegidos, e a velocidade das transações geralmente revela a qualidade do serviço, fator que merece atenção antes de depositar. A biblioteca de títulos costuma ser diversificado e atrativo, desde jogos de máquina até roleta e blackjack, isso agrada diferentes perfis de jogadores. O cassino ao vivo atrai jogadores por conta dos dealers reais, pois a qualidade do stream define a imersão do jogador de forma significativa a cada rodada. O suporte ao cliente tem grande valor, especialmente quando é preciso ajuda, por isso um atendimento eficiente deve estar disponível a qualquer hora, proporcionando uma experiência tranquila em qualquer situação. A velocidade dos saques demonstra a seriedade da plataforma, então termos claros de saque indicam qualidade a longo prazo para o jogador. O jogo responsável tem que ser uma prioridade, então limites de depósito realmente promovem hábitos saudáveis de maneira eficaz no longo prazo. O registro regulatório representa a garantia básica de proteção, pois confirma a fiscalização, o que traz tranquilidade antes do cadastro, idealmente com atenção. Dito isso, Em resumo uma seleção acertada vem de análise, então avalie com cuidado, verifique os termos e condições e mantenha o controle. Merita attenzione di regola casino online stranieri, solo quando verifichi la licenza, invece di credere alla pubblicita, con la dovuta attenzione, per valutare ogni aspetto. Il gioco responsabile deve restare importante, percio gli avvisi sul tempo danno un senso di controllo in ogni momento, senza perdere equilibrio prima di decidere. Una licenza valida e quasi sempre l elemento chiave di sicurezza, perche conferma la vigilanza, cosa da non ignorare prima di registrarti, con attenzione prima della scelta. I bonus fanno impressione, ma il loro guadagno effettivo dipende dal rollover, percio conviene leggerli con calma, in modo chiaro prima della scelta. I metodi di pagamento dovrebbero essere flessibili, e la durata del processo spesso riflette l onesta, cosa da verificare, in modo chiaro prima della scelta. Inoltre, La libreria di giochi di solito e variata, da giochi con jackpot fino a roulette, il che assicura varieta ogni giorno, con valutazioni attente prima della scelta. Il casino dal vivo fa impressione grazie a un atmosfera autentica, e la qualita dello stream decide l esperienza dell intera sessione, in modo evidente prima della scelta. Un assistenza cortese crea fiducia, soprattutto quando qualcosa va chiarito, percio la chat dal vivo valgono oro in ogni momento, con risposte precise prima della scelta. I prelievi rivelano la verita su la qualita del servizio, percio limiti chiari danno tranquillita a lungo termine, con effetti visibili prima della scelta. Un approccio prudente conta sempre, percio i limiti di deposito aiutano a mantenere la lucidita ogni giorno, con attenzione costante prima della scelta. Una licenza affidabile e di solito l elemento chiave di sicurezza, perche garantisce regole chiare, cio che da tranquillita prima di registrarti, con attenzione durante il confronto. I premi iniziali sono allettanti, ma il loro guadagno effettivo deriva dal regolamento, percio vanno verificati con calma, in modo chiaro durante il confronto. Le opzioni di incasso dovrebbero essere comodi, e la durata del processo in genere rivela l approccio dell operatore, cosa da verificare, in modo chiaro durante il confronto. La libreria di giochi si presenta ampia, da giochi con jackpot fino a baccara, il che accontenta giocatori diversi ogni giorno, con valutazioni attente durante il confronto. In breve una decisione consapevole poggia sui numeri, quindi non avere fretta, leggi con attenzione le regole e usa il buon senso, in qualsiasi momento.
 

25 May Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Posted at 13:15h in News by
0 Likes
  • EMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which did not include complement inhibitors, at Week 26
  • Mean hemoglobin levels in the EMPAVELI group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019)
  • 91% of patients on EMPAVELI were transfusion free compared to 22% on standard of care (p<0.0001)
  • The safety profile of EMPAVELI was consistent with previous studies

WALTHAM, Mass. and STOCKHOLM, Sweden, May 25, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today reported positive top-line results from the Phase 3 PRINCE study evaluating the efficacy and safety of EMPAVELI™ (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) who are treatment naïve, meaning they had not received a complement inhibitor within three months before entering the study.

EMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization and reduction in lactate dehydrogenase (LDH) compared to standard of care, which did not include complement inhibitors, at Week 26.

  • 86% of EMPAVELI-treated patients achieved hemoglobin stabilization compared to 0% of patients on standard of care (p<0.0001). Hemoglobin stabilization was defined as an avoidance of a >1 g/dL decrease in hemoglobin levels in the absence of transfusions.
  • Mean LDH in the EMPAVELI group decreased by 90% from a baseline of 2151 U/L [9.5x upper limit of normal (ULN)] to 211 U/L, which is within the normal range, compared to a 14% reduction on standard of care from a baseline of 1946 U/L (8.6x ULN) to 1681 U/L (7.4x ULN) (p<0.0001).

“The positive PRINCE data showed that EMPAVELI provided clinically meaningful improvements across multiple measures that are important for patients and build on our recent FDA approval of EMPAVELI in PNH,” said Federico Grossi, M.D., Ph.D., chief medical officer, Apellis. “Combined with previous studies, these results emphasize the potential of EMPAVELI to provide disease control for all adults with PNH regardless of prior treatment.”

EMPAVELI also achieved statistical superiority on several secondary endpoints, including improvements in hemoglobin levels and transfusion avoidance, compared to standard of care, which did not include complement inhibitors.

  • Mean hemoglobin levels in the EMPAVELI group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from a baseline of 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019).
  • 91% of patients on EMPAVELI were transfusion free compared to 22% on standard of care (p<0.0001).

The safety profile of EMPAVELI was consistent with previous studies. At Week 26, 9% of patients in the EMPAVELI group experienced a serious adverse event (SAE) compared to 17% on standard of care. One death was reported in each group, and neither were related to treatment. No cases of meningitis or thrombosis were reported in either group. The most common adverse events reported during the study in the EMPAVELI and standard of care groups, respectively, were injection site reaction (30% vs. 0%),
hypokalemia (13% vs.11%), and fever (9% vs. 0%).

“The PRINCE study results reinforce the efficacy and safety profile of EMPAVELI in PNH,” said Ravi Rao, head of research and development and chief medical officer at Sobi. “Our hope is to contribute to an improvement of care and to make a difference in the lives of people with this rare blood disease.”

Detailed results from the PRINCE study will be presented at medical congresses.

About the PRINCE Study
The PRINCE study (NCT04085601) is a 2:1 (EMPAVELI: standard of care) randomized, multi-center, open-label, controlled Phase 3 study in 53 treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH). The primary objective of this study was to establish the efficacy and safety of EMPAVELI™ (pegcetacoplan) in patients who have not received treatment with any complement inhibitor within three months prior to screening. During the 26-week randomized, controlled period, patients received either 1080 mg of EMPAVELI twice weekly or standard of care therapy, which did not include complement inhibitors. Patients in the standard of care group had the option to escape to the EMPAVELI group if their hemoglobin decreased 2 g/dL or more from their baseline value.

The study was conducted in collaboration with SFJ Pharmaceuticals, who supported the development of EMPAVELI in PNH. SFJ is a global drug development company, which provides a unique and highly customized co-development partnering model for the world’s top pharmaceutical and biotechnology companies.

About EMPAVELI™ (pegcetacoplan)
EMPAVELI™ (pegcetacoplan) is the first and only approved therapy targeting C3, the central protein in the complement cascade. EMPAVELI acts proximally in the complement cascade controlling both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis. EMPAVELI is approved in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).

U.S. Important Safety Information for EMPAVELI

BOXED WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

  • Meningococcal infections may occur in patients treated with EMPAVELI and may become rapidly life-threatening or fatal if not recognized and treated early. Use of EMPAVELI may predispose individuals to serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B.
  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria.
  • Vaccinate patients at least 2 weeks prior to administering the first dose of EMPAVELI unless the risks of delaying therapy with EMPAVELI outweigh the risk of developing a serious infection.
  • Vaccination reduces, but does not eliminate, the risk of serious infections. Monitor patients for early signs of serious infections and evaluate immediately if infection is suspected.
  • EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the EMPAVELI REMS, prescribers must enroll in the program.

CONTRAINDICATIONS

  • Hypersensitivity to pegcetacoplan or to any of the excipients
  • Not currently vaccinated against certain encapsulated bacteria, unless the risks of delaying EMPAVELI treatment outweigh the risks of developing a bacterial infection with an encapsulated organism
  • Unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria
The use of EMPAVELI may predispose individuals to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B (Hib). To reduce the risk of infection, all patients must be vaccinated against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI.

For patients without known history of vaccination, administer required vaccines at least 2 weeks prior to receiving the first dose of EMPAVELI. If immediate therapy with EMPAVELI is indicated, administer required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis.

Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider discontinuation of EMPAVELI in patients who are undergoing treatment for serious infections.

EMPAVELI REMS
Because of the risk of serious infections, EMPAVELI is available only through a restricted program under a REMS. Under the EMPAVELI REMS, prescribers must enroll in the program and must counsel patients about the risk of serious infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria. Enrollment and additional information are available by telephone: 1-888-343-7073 or at www.empavelirems.com.

Infusion-Related Reactions
Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria) have occurred in patients treated with EMPAVELI. One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.

Monitoring PNH Manifestations after Discontinuation of EMPAVELI
After discontinuing treatment with EMPAVELI, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues EMPAVELI for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI.

Interference with Laboratory Tests
There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.

ADVERSE REACTIONS
The most common adverse reactions (incidence ≥10% of patients) with EMPAVELI vs. eculizumab were injection-site reactions (39% v. 5%), infections (29% v. 26%), diarrhea (22% v. 3%), abdominal pain (20% v. 10%), respiratory tract infection (15% v. 13%), viral infection (12% v. 8%), and fatigue (12% v. 23%).

USE IN SPECIFIC POPULATIONS

Females of Reproductive Potential
EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.

Please see full Prescribing Information, including Boxed WARNING regarding serious infections caused by encapsulated bacteria, and Medication Guide.

About Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH is a rare, chronic, life-threatening blood disorder characterized by the destruction of oxygen-carrying red blood cells through extravascular and intravascular hemolysis. Persistently low hemoglobin can result in frequent transfusions and debilitating symptoms such as severe fatigue, hemoglobinuria and difficulty breathing (dyspnea).

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit http://apellis.com.

About Sobi™
Sobi is a specialized international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, Middle East, and Asia. In 2020, Sobi’s revenues amounted to SEK 15.3 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements in respect of the expected closing of the exchanges. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the conditions for the closing of the exchanges will be satisfied and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q with the Securities and Exchange Commission on April 28, 2021 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Apellis
Media:
Lissa Pavluk
media@apellis.com
617.977.6764

Investors:
Argot Partners
apellis@argotpartners.com
212.600.1902

Sobi
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com

Maria Kruse, Corporate Communication & Investor Relations
+ 46 767 248 830
maria.kruse@sobi.com